A comprehensive real-world pharmacovigilance investigation evaluating post-marketing surveillance databases has detected a statistically significant disproportional reporting signal for depression-related adverse events following administration of the adsorbed anthrax vaccine. Published in Infectious Diseases of Poverty, the investigation combined spontaneous report screening from the United States Vaccine Adverse Event Reporting System and the Food and Drug Administration Adverse Event Reporting System with machine learning risk prediction and comparative transcriptomic analyses. Across 9,446 adverse event reports associated with the adsorbed anthrax vaccine extracted from the vaccine database between 1993 and 2025, researchers identified 180 depression-related cases, yielding an overall reporting odds ratio of 5.02 with a 95 percent confidence interval spanning 4.33 to 5.81. The authors emphasized that spontaneous reporting databases cannot quantify true incidence or demonstrate biological causality, framing their conclusions as hypothesis-generating evidence that warrants targeted post-vaccination mental health monitoring and systematic epidemiological follow-up.
Anthrax is a life-threatening, globally distributed zoonotic infection caused by Bacillus anthracis that remains endemic in resource-limited regions where human-livestock contact and sanitation challenges heighten exposure risks. Global vigilance surrounding the pathogen escalated markedly following the 2001 United States bioterrorist mailings, which contaminated more than 30,000 individuals and resulted in five fatalities, underscoring its dangerous potential as an aerosolized biological weapon. To protect vulnerable personnel, the adsorbed anthrax vaccine, marketed under the brand name BioThrax by Emergent BioSolutions, was authorized by United States regulatory authorities as the sole preexposure prophylaxis for adults aged 18 to 65 years at elevated risk of exposure. Although regulatory assessments have consistently documented local injection-site soreness, fever, malaise, and myalgia as expected post-vaccination responses, mental health outcomes have remained sparsely evaluated. Prior investigations by the Centers for Disease Control and Prevention had produced conflicting results: an observational study of 576 participants noted a marginal unadjusted decline in generic mental health survey scores at 30 months that lost statistical significance after controlling for confounders, while a randomized trial of 1,562 participants showed no mental score divergence over 42 months.
To rigorously address this evidentiary deficit, the investigative team established an analytical protocol adhering to the international Reporting of a Disproportionality Analysis for Drug Safety Signal Detection Using Individual Case Safety Reports in Pharmacovigilance guideline. Working with the Vaccine Adverse Event Reporting System, the authors linked demographic, vaccination, and symptom data tables, removing foreign reports, entries lacking product identifiers, and procedural vaccination errors that lacked clinical adverse symptoms. In parallel, the researchers retrieved safety reports from the Food and Drug Administration Adverse Event Reporting System spanning seven antibacterial therapeutics commonly indicated for anthrax prophylaxis or active management: penicillin, levofloxacin, doxycycline, moxifloxacin, minocycline, ceftriaxone, and meropenem. Adverse event terms across both datasets were classified according to the Medical Dictionary for Regulatory Activities version 27.0. Signal detection relied on four mathematical methodologies: reporting odds ratios, proportional reporting ratios, the Bayesian Confidence Propagation Neural Network, and Multinomial Gamma Poisson Shrinkage algorithms, establishing an event as a signal if threshold values were achieved across these recognized metrics.
Descriptive analysis of the complete cohort of 9,446 anthrax vaccine reports revealed prominent structural and longitudinal patterns across the 32-year surveillance window. BioThrax produced by Emergent BioSolutions accounted for 69.2 percent of all logged records, with subcutaneous injection representing the predominant administrative route at 41.5 percent and the left arm serving as the primary anatomical injection site in 32.6 percent of documented events. First-dose administrations constituted 21.3 percent of the reporting volume, while 18.5 percent involved unspecified schedule intervals. Longitudinal surveillance tracking exhibited noticeable peaks in total reporting volume: an initial surge occurred between 1998 and 2000, peaking at 1,004 annual reports, followed by a secondary apex of 1,102 reports in 2003 and a third elevation of 727 reports in 2008, before subsiding into a persistent downward trajectory with fewer than 100 annual reports recorded in recent years. Geographic breakdowns showed that California and Virginia accounted for 6.8 percent and 6.2 percent of total vaccine adverse event reports, respectively, whereas Puerto Rico accounted for 24.4 percent of general mental health reports and 44.7 percent of depression-specific records.
Within the subset of 180 depression-related adverse event cases linked to the adsorbed anthrax vaccine, distinct demographic concentrations were observed. Male individuals represented 78.2 percent of cases with 141 individual reports, whereas female recipients constituted 17.3 percent with 31 reports, and 4.5 percent lacked documented sex identifiers. Working-age adults between 31 and 45 years accounted for nearly half of the depression cohort at 49.1 percent with 89 cases, followed by young adults aged 18 to 30 years representing 33.5 percent with 60 cases; no reports were recorded among individuals younger than 18 or older than 65 years. Clinical severity assessments revealed that 44.1 percent of these cases, representing 79 reports, met regulatory criteria for serious adverse events. Permanent disability was documented in 30.2 percent of cases, comprising 55 reports, while life-threatening developments were recorded in 17.9 percent, comprising 32 reports.
When individual preferred terms were evaluated within the depression classification category, disproportionality metrics demonstrated significant variation across clinical diagnostic designations. The general preferred term Depression encompassed the vast majority of records with 169 cases, demonstrating a robust positive signal characterized by a reporting odds ratio of 6.96, a proportional reporting ratio of 6.94, an empirical Bayesian geometric mean of 6.77, and an information component of 2.76. Major Depression accounted for four cases and similarly achieved statistically significant positive disproportionality, yielding a reporting odds ratio of 4.55 with a 95 percent confidence interval between 1.69 and 12.24. Conversely, the term Depressed Mood accrued seven cases and failed to establish a statistically significant signal, showing a reporting odds ratio of 0.72. Sensitivity analyses that removed all reports involving concurrent administration of additional vaccines retained 119 unconfounded depression-related cases, which preserved a positive reporting signal with an odds ratio of 4.97 and a 95 percent confidence interval from 4.14 to 5.96.
Demographic stratification highlighted substantial heterogeneity across recipient subgroups. Among male vaccine recipients across 142 reports, the disproportionality signal remained elevated with a reporting odds ratio of 6.11, while female recipients across 33 reports exhibited a comparatively lower reporting odds ratio of 3.28. Age-stratified analysis revealed that recipients aged 46 to 65 years generated the strongest association signal, demonstrating an odds ratio of 10.31 across 35 reports, compared to an odds ratio of 5.55 among those aged 31 to 45 years and 2.98 among recipients aged 18 to 30 years. Temporal assessment showed a marked clustering of depressive complaints shortly after immunization. Among 113 cases with precise temporal records, the median time to symptom onset was 10 days, with an interquartile range extending from 1 to 81 days. Density distribution curves demonstrated that event onsets peaked sharply within the initial 30 days post-vaccination, and Weibull distribution modeling generated a shape parameter beta of 0.51, confirming an early-failure operational pattern in which new incident reporting hazards diminish progressively over time.
To explore clinical predictors of depression reporting, the researchers trained and evaluated seven distinct machine learning frameworks on a 70 percent training partition and validated them on a 30 percent holdout test set using EasyR software. Across the evaluated models, Random Forest demonstrated the highest discriminative capacity, achieving an area under the receiver operating characteristic curve of 0.89 alongside a specificity of 0.999 and a positive predictive value of 0.80, though tempered by a modest sensitivity of 0.213. The Extreme Gradient Boosting model delivered the most balanced comprehensive metrics, attaining the highest balanced accuracy at 0.624, an area under the curve of 0.856, an overall accuracy of 0.976, and a specificity of 0.995, with a sensitivity of 0.253 and an F1 score of 0.355. Naive Bayes maximized sensitivity and recall at 0.960 but performed poorly in discrimination, yielding a specificity of 0.177 and an overall accuracy of 0.197. Support vector machines and least absolute shrinkage and selection operator regression models demonstrated limited clinical predictive utility, characterized by absent or zero sensitivity values.
Interpretability analysis utilizing Shapley Additive Explanations pinpointed the individual features driving predictive algorithm decisions. The occurrence of a serious adverse event emerged as the primary determinant with a mean Shapley value of 0.601, followed closely by time to onset at 0.561, patient allergy history at 0.434, and recipient age at 0.321. Technical vaccination variables, including anatomical site and dose number, exerted minimal predictive influence, registering mean Shapley contributions at or below 0.078. Regularized regression via the least absolute shrinkage operator retained serious adverse events as the sole decisive predictor at the one standard error penalty threshold. Subsequent Cox proportional hazards survival modeling confirmed that the presence of a serious adverse event increased the risk of early depressive event onset by a hazard ratio of 3.829 with a 95 percent confidence interval from 2.644 to 5.546, while advanced age contributed an incremental hazard ratio of 1.031 per year.
Expanding surveillance to therapeutic countermeasures, the investigators screened 1,763 depression-related adverse event reports linked to seven anthrax-relevant antibacterial agents in the Food and Drug Administration database. Disproportionality calculations revealed statistically significant positive reporting signals for only two agents: levofloxacin, with 634 cases yielding a reporting odds ratio of 1.37, and doxycycline, with 332 cases demonstrating an odds ratio of 1.53. In contrast, penicillin, moxifloxacin, minocycline, ceftriaxone, and meropenem exhibited statistically significant negative disproportionality signals, indicating lower reporting frequencies for depressive events than expected across database baselines. Evaluating the clinical priority of positive therapeutic signals through a composite index incorporating case totals, lower confidence bounds, mortality proportions, and regulatory designated medical event criteria, the researchers classified Depression Suicidal, which comprised 32 reports and an odds ratio of 2.61, as a moderate clinical priority, whereas four other positive depressive terms were designated low priority.
To investigate biological plausibility, the study integrated transcriptomic re-analyses of two independent public microarrays from the Gene Expression Omnibus database. Evaluating peripheral blood mononuclear cells exposed to Bacillus anthracis lethal toxin in dataset GSE34407 against unexposed controls identified 1,313 significantly upregulated and 382 downregulated genes at absolute log fold changes greater than 1.5 and adjusted p-values under 0.05. Comparison with dataset GSE38206, which analyzed peripheral blood mononuclear cells from patients in their first week of major depressive disorder, revealed 355 upregulated and 284 downregulated transcripts. Intersection analysis isolated 37 shared upregulated genes between the two pathological contexts. Functional enrichment through Gene Ontology and Kyoto Encyclopedia of Genes and Genomes mapping demonstrated convergent activation of neutrophil-mediated inflammatory pathways, including neutrophil activation involved in immune response, neutrophil degranulation, and ficolin-1-rich granule structures, alongside significant enrichment of the Yersinia infection signaling cascade.
The study authors contextualized these computational and laboratory signals within known neuroimmune pathways, proposing that systemic inflammatory cascades triggered by severe adverse reactions may induce pro-inflammatory cytokines such as interleukin-6 and tumor necrosis factor-alpha, compromising blood-brain barrier integrity and altering central neurotransmission. For antibacterial agents, blood-brain barrier penetration by levofloxacin may inhibit gamma-aminobutyric acid receptors to disrupt inhibitory neurotransmission, whereas doxycycline-induced gut dysbiosis may stimulate indoleamine 2,3-dioxygenase activity, diverting tryptophan metabolism toward neurotoxic kynurenine metabolites. Nevertheless, the authors detailed substantial methodological limitations: spontaneous reporting systems lack unexposed population denominators, preventing absolute incidence or risk calculations, and suffer from underreporting, variable record quality, and reporting biases. Crucially, military cohorts receiving the anthrax vaccine experience operational stressors, combat deployments, and post-traumatic stress that could not be fully adjusted for in passive registries. The transcriptomic model relied on lethal toxin as a surrogate rather than the vaccine itself. Consequently, these findings represent hypothesis-generating safety signals requiring rigorous validation in controlled epidemiological cohorts.
Subject of Research: Pharmacovigilance and transcriptomic analysis of depression-related adverse event signals associated with adsorbed anthrax vaccine and related antibacterials
Article Title: Real-world analysis of depression-related adverse events associated with the adsorbed anthrax vaccine: integrating pharmacovigilance signals, machine learning risk prediction, and transcriptomic mechanisms
Article References: Qing, G., Zhao, Y., Yang, J., & Wang, G. (2026). Real-world analysis of depression-related adverse events associated with the adsorbed anthrax vaccine: integrating pharmacovigilance signals, machine learning risk prediction, and transcriptomic mechanisms. Infectious Diseases of Poverty, 15(1), Article 86. https://doi.org/10.1186/s40249-026-01483-0
Image Credits: AI Generated
DOI: 10.1186/s40249-026-01483-0
Keywords: adsorbed anthrax vaccine, BioThrax, pharmacovigilance, VAERS, FAERS, depression-related adverse events, disproportionality analysis, reporting odds ratio, machine learning, XGBoost, Random Forest, SHAP interpretability, time to onset, Bacillus anthracis, doxycycline, levofloxacin, neutrophil degranulation, transcriptomics, clinical priority assessment
News Source: Glenn Wilkins. (November 19, 2026). Study Identifies Depression Reporting Signal Linked to Adsorbed Anthrax Vaccine. Scienmag.



